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Background: Thailand faces a significant burden in terms of treating and managing degenerative and chronic
diseases. Moreover, incidences of rare diseases are rising. Many of these—such as diabetes, cancer, and inherited
inborn metabolic diseases—have no definite treatments or cure. Meanwhile, advanced health biotechnology has
been found, in principle, to be an effective solution for these health problems.
Methods: Qualitative approaches were employed to analyse the current situation and examine existing public
policies related to advanced health biotechnologies in Thailand. The results of this analysis were then used to
formulate policy recommendations.
Results: Our research revealed that the system in Thailand in relation to advanced health biotechnologies is
fragmented, with multiple unaddressed gaps, underfunding of research and development (R&D), and a lack of
incentives for the private sector. In addition, there are no clear definitions of advanced health biotechnologies, and
coverage pathways are absent. Meanwhile, false advertising and misinformation are prevalent, with no responsible
bodies to actively and effectively provide appropriate information and education (I&E). The establishment of a
specialised institution to fill the gaps in this area is warranted.
Conclusion: The development and implementation of a comprehensive national strategic plan related to advanced
health biotechnologies, greater investment in R&D and I&E for all stakeholders, collaboration among agencies,
harmonisation of reimbursement across public health schemes, and provision of targeted I&E are specifically
recommended.
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Although Thailand has been classified as a technology-
recipient country [1], significant research and develop-
ment (R&D) in several areas of biomedicine has been
undertaken in recent years [2]. A number of excellence
centres for biomedical research have been established in
universities and other institutions, some of which work on
advanced health biotechnologies. Furthermore, a number
of private companies for stem cell research are operating
in the country [3-8].
Prior to 2009, stem cell therapy interventions in clin-
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distribution, and reproduction in any mediumled to many incidents of exaggerated and false claims
and a number of cases of misconduct among clinicians
offering stem cell therapy, which prompted increased
worldwide attention on these issues [9-12]. In Thailand,
stem cell therapy was provided by a number of institu-
tions and individuals before sufficient research and
development had been undertaken to ensure the safety
of the procedure.
Despite the fact that there is significant regulation of
stem cell research and unproven treatment is now forbid-
den, there continue to be breaches in the law. However,
many positive advances in the field of pharmacogenomic/
pharmacogenetic (PGx) testing have been made in recent
years, with some testing already taking place in public
hospitals [13]. At the same time, however, little attentionentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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therapy, which have advanced more slowly as a result.
To plan more effectively for the future, the Thai
National Science, Technology and Innovation Policy
Office commissioned the Health Intervention and Tech-
nology Assessment Program (HITAP), a research arm of
the Health Ministry, to conduct research for the develop-
ment of advanced health biotechnologies in Thailand.
This paper provides an assessment of the current situation
in Thailand, including a review of relevant public policy.
Based on this review and analysis, we make a number of
policy recommendations.
Methods
A review of existing literature on advanced health bio-
technologies in Thailand was undertaken using relevant
bibliographic databases, search engines, and websites. The
data was then organised into a conceptual framework.
For benchmarking purposes, research was also conducted
for regions such as the United States and Europe. This
literature review was complemented by information gar-
nered during four focus group discussions involving a
number of relevant stakeholders, including Thai research-
ers, administrators of research institutes, policymakers,
regulators, patient representatives, and physicians. These
took place between October and December 2011 in the
premises of HITAP. Expert opinions and data on the
current situation and existing policies were also col-
lected following attendance at an external consultation,
convened by the National Science and Technology
Development Agency (NSTDA). Two case studies on
facilitators and barriers to the adoption and diffusion of
advanced health biotechnologies were developed, and
the findings from these also informed the study. Finally,
two consultative meetings were held in HITAP in June
2011 and March 2012 to gather additional information,
verify the initial results, and fine-tune the recommenda-
tions. Finally, triangulation was applied to verify the
findings and recommendations. More detail on the re-
search methods, including details of the relevant materi-
als and definitions can be found in the full report, which
is available upon registration at www.hitap.net/en/re-
search/10664.
Review of the situation and public policies
Research and development
Our research revealed that, while a policy document on
advanced health biotechnologies has been developed by
the NSTDA, [14] it fails to provide clear policy directions
for undertaking research in this area. However, this find-
ing is disputed by the key informant of the medical
cluster of the NSTDA, which is responsible for R&D,
technology transfer, human resources, and infrastructure
development associated with science and technology.Nevertheless, as a result of the complex management
structures that are in place at the NSTDA (each cluster
has its own director), it is unclear how the policy outlined
in the paper is actually implemented. This lack of a clear
national policy and recommendations on research in
advanced health biotechnologies has meant that many
R&D activities are conducted outside of the scope of the
National Research Council (NRC) and NSTDA. There is
also very little communication between the relevant na-
tional bodies on which areas of advanced health biotech-
nologies in Thailand are supported.
It is recognised that large pharmaceutical firms may be
hesitant to conduct R&D on advanced health biotech-
nologies for a number of reasons, including uncertainty
surrounding the potential benefits and risks of these tech-
nologies, high production costs, strict regulations, and lo-
gistical difficulties [15]. Moreover, to overcome this, it
may be necessary to develop innovative financial mecha-
nisms for R&D and public-private partnerships (PPPs) in
this field [16-20]. However, with no clear national policy
in place, the benefits of such partnerships might not be
maximised or might even result in serving mainly the
commercial interests of those involved.
Owing to the lack of uniformity on international eth-
ical standards in biomedical R&D, very little attention
on this has been paid in Thailand. The system for the
ethical approval of medical research has improved very
little in four decades. One recent survey found that
many of these ethical committees have poor capacity,
lacking codes of conduct and proper regulations to avoid
conflicts of interest [21]. In the area of advanced health
biotechnologies, the situation may be worse even than in
conventional biomedical research because of the rapid
progress of scientific knowledge, involvement of human
donors, and disclosure of close relatives’ genetic infor-
mation, inter alia [22,23]. As a result, researchers have
tended to conduct R&D without applying for ethical
clearance. Moreover, even when ethical clearance is
sought, it is frequently given routinely, with little or no
analysis of the ethical implications of the research.
There have also been several cases where advanced
health biotechnologies were applied in ways that violated
public trust [24-26]; as a consequence, the Medical
Council (MC), which is the medical professional regula-
tory body, has drafted stricter regulations that explicitly
cover all stem cell research and practice conducted by
medical doctors (except for bone marrow transplant-
ation, which is viewed as a conventional procedure).
Under these new regulations, all physicians wishing to
undertake research on stem cell therapy must obtain
both scientific and ethical approval from the MC. How-
ever, Thai experts suggest that many scientists regard
this regulation as an obstacle to advancement in this
field of research. At the same time, it appears that these
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adequate regulator capacity and the potential for conflict
of interest [27]. This echoes a case in the US, where the
California Institute for Regenerative Medicine (CIRM)—
the funding agency with the largest amount of public
funds in the state—had on its board a number of experts
from leading research organisations who were respon-
sible for approving grant applications, including those of
their own institutes and their competitors [28].
Despite this, the CIRM funding approach has a number
of notable benefits. Significantly, it implements a system
where more stable funding of research is guaranteed by
the provision of grants over several years, rather than on
a year-by-year basis (which had been the case in previous
years) [28]. This year-by-year allocation system of the li-
mited government budget is the current practice among
almost all Thai research granters, including the NRC and
NSTDA. This system hampers the progress of research,
as suggested by the Tufts Center for the Study of Drug
Development, which estimates that one advanced health
biotechnology product requires an average of 8 years at a
cost of USD 1.2 billion, compared to the average period
of seven years and cost of USD 800 million for one con-
ventional medical product [28].
Authorisation
Many advanced health biotechnologies do not fall clearly
into the classic categories used by many regulatory agen-
cies. In Thailand, the Thai Food and Drug Administration
(TFDA), Department of Medical Sciences (DMSc), and
MC share responsibility for the authorisation of medical
products, medical and laboratory practice, and related ad-
vertising. These organisations do not have a clear and
uniform way of defining and classifying advanced health
biotechnologies. In contrast, in Europe a consensus was
reached in 2007, in the form of the Advanced Therapies
legal and regulatory framework (Regulation (EC) No
1394/2007). In addition, the US Food and Drug Adminis-
tration (FDA) has also developed definitions for regenera-
tive medicine products (neither framework covers PGx
tests, which fall under a different classification). Having
clear definitions and classification is very important, as
regulators can use them to set standards of information
requirements for authorisation, reimbursement, and post-
authorisation activities.
Evidence suggests that, in Thailand, there is both insu-
fficient demand for regulation of advanced health bio-
technologies and inadequate capacity to implement this
regulation should the demand arise. This results from a
number of factors. First, there is a lack of clarity regarding
which body would be responsible for regulating these
kinds of technologies. For instance, the TFDA oversees
only pharmaceutical products (including biologics) and
medical devices, unlike the European Medicines Agency(EMA) and the FDA, which have specific expertise in
these kinds of technologies. Furthermore, private biotech-
nology companies are not pushing for approval of their
products because this may not suit their business needs;
for example, many PGx tests are locally produced by
healthcare facilities, which renders them outside the remit
of the TFDA’s regulations. In addition, the Thai market
for advanced health biotechnologies is relatively small
and, as such, private biotechnology manufacturers do not
prioritise marketing in Thailand.
Post-authorisation
We have classified post-authorisation regulatory activities
into the following four areas:
Post-marketing surveillance In the US, the FDA plays
a major role in post-marketing surveillance of advanced
health biotechnologies, including cell therapy, tissue
engineering, and other regenerative medicines [29]. In
Europe, the EMA is responsible for product surveil-
lance, but it varies in the case of monitoring of services,
which is conducted by either national drug regulatory
agencies or health care quality inspectorates [30]. Given
that there is no clear definition or classification of
advanced health biotechnologies in Thailand, we pre-
dict that ensuring safety, effectiveness, and quality of
these technologies after approval is likely to be a chal-
lenge. Recently, the MC prohibited any stem cell ther-
apies except bone marrow transplantation. This should
only be regarded as a short-term solution to ensure the
safety, effectiveness and quality of stem cell treatment;
moreover, this regulation does not extend to surveil-
lance after approval, which means that many therapies
continue to be conducted without sufficient regulation
or monitoring.
Quality assurance of laboratories in the service sector
There is no national authority in place in Thailand to
regulate laboratory practice and quality related to
advanced health biotechnologies—although the DMSc is
responsible for Good Laboratory Practice (GLP) compli-
ance monitoring. The DMSc is also increasing the ca-
pacity of its 15 laboratories across the country in order
to perform a number of PGx tests, mainly focusing on
preventing severe adverse reactions from anti-retroviral
therapy and epilepsy treatment. It is unlikely that the
DMSc will support the private laboratories in their at-
tempt to build their PGx testing capacity. In addition,
the Department has no plan to widen its scope to sup-
port lab activities related to regenerative therapies [31].
Quality assurance of medical services The quality as-
surance system of medical services in Thailand is passive;
that is, the MC only comes into play when complaints are
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ical practitioners if their practice is substandard or negli-
gent, or if they make exaggerated claims or undertake
false advertising, but only after a report or complaint is
made. Patients can also file a lawsuit in the civil and crim-
inal courts. In addition, the MC controls the quality of
services by defining those who are permitted to provide
various services. This means that only those who are
licensed as physicians can prescribe and perform medical
care. At present, because there is no individual or body
specifically tasked with setting standards of care for
advanced health biotechnologies, undertaking quality con-
trol of medical services in this area is certain to be a
challenge.
Promotion/advertisement regulation In Europe, the
advertising of regenerative medicine services has been
prohibited by the European Commission, while the EMA
regulates the advertising of advanced therapy products.
The US allows the advertising of prescription-only
drugs, and, in principle, this should extend to approved
advanced health biotechnology products. However, despite
the FDA’s considerable capacity, problems are still en-
countered in terms of regulating advertisement and sales
for approved advanced health biotechnology products. In
particular, there are calls to restrict direct-to-consumer
(DTC) genetic test advertisements and sales. In Thailand,
the DTC sale of prescription-only products is prohibited
by law, and the legal regulation of medical service adver-
tising is supervised by the Bureau of Sanatorium and Art
of Healing. Despite this, there are still many public adver-
tisements for advanced health biotechnologies, almost all
of which make exaggerated claims [25,32,33].
Reimbursement and related service provision models
The reimbursement of products related to advanced
health biotechnologies is challenging even in the US and
Europe. The assessment of safety, efficacy/effectiveness,
acceptability, and other social consequences is difficult
and varies depending on context, due to differences in pa-
tient and clinician behaviour and delayed health out-
comes, among others. Moreover, the information available
for reimbursement of advanced health biotechnology pro-
ducts is often inadequate when compared to that available
for conventional treatment. The third party payer is often
pressured to approve these technologies because of the
lack of available alternatives. Thus, a number of scholars
have recommended that those payers that are faced with a
promising advanced health biotechnology that may im-
prove patient safety and outcomes, but which still has
significant uncertainty associated with it, introduce cover-
age with evidence development (CED) [34,35]. For ex-
ample, in 2009, the US Center for Medicare and Medicaid
Services initiated CED for warfarin PGx testing, given theclinical promise but inconclusiveness or contrary results
that had emerged on the back of the few small rando-
mised controlled trials (RCTs) that had been conducted at
the time [35].
The service and financing models that are currently
available in Thailand were designed for conventional med-
ical technologies. Commonly, public providers buy medi-
cines and medical devices (including medical supplies)
from the private sector and manage them themselves,
which can be seen as a pure purchaser-supplier relation-
ship. The National Health Security Office (NHSO), which
manages the Universal Health Coverage Scheme—the lar-
gest of the three public health plans in Thailand, also buys
commodities at the central level and allocates them to
local public providers. The latter business model is be-
lieved to increase system efficiency because the buyer has
more price negotiation power, although this may come at
the expense of future market competition and the provi-
ders’ autonomy [36]. In recent years, the NHSO has
started to buy services from private companies, for ex-
ample, cataract surgery, renal dialysis, and heart surgery.
In addition, some public hospitals lease public space out
to private companies to develop and operate service deli-
very units (SDUs), such as medical scanning or renal dia-
lysis units; these arrangements operate under informal
contracts [37]. This does not comply with government
regulations and creates difficulties [38]. For instance, one
study has indicated that most public hospitals do not have
access to sufficient information and do not exert much
power when conducting negotiations with private com-
panies. As a result of this misconduct, these privately-run
SDUs are unevenly introduced across regions, sometimes
resulting in the overprescribing of services [37].
We believe that, if advanced health biotechnologies—
and regenerative medicine in particular— are to be made
available under public health plans, their delivery model is
likely to take a similar form to that of the privately-run
SDUs; this is because, while the technological know-how
will belong to private sector entities, these entities will not
be able to operate these services completely on their own.
As a consequence, new models need to be developed for
PPPs in the health sector in Thailand that can be tailored
specifically tor advanced health biotechnologies.
Information and education
It is widely recognised that provision of information and
education (I&E) for all stakeholders is critical if society
is to maximise the benefits from advanced health bio-
technologies. For instance, most clinicians in the US and
Europe have little knowledge on genomic medicine or
the benefits and risks of specific PGx tests. Moreover,
many of them are concerned about the consequences of
their inadequate knowledge and how this could potentially
lead to mistakes and even liability [39]. This appears to
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into clinical practice.
In most countries, including Thailand, related research
organisations and networks provide public I&E; however,
given the limited capacity and the potential for conflict of
interest, society should not rely only on these sources. In
the US, the National Human Genomics Research Institute
(NHGRI) established the Education and Community In-
volvement Branch (ECIB), a body specifically responsible
for public education on genomics-related issues.
Similarly, many non-governmental organisations (NGOs)
and patient advocacy groups have in place key policies to
disseminate I&E as part of their strategy to garner public
support for advanced health biotechnologies. Evidence
from the US and EU suggests that, while NGO provision
of I&E can be very effective, it can also create misunder-
standings. In Thailand ad hoc public I&E sharing was con-
ducted by the TFDA at the time when stem cell banks
became a public interest. Currently, no public body ac-
tively provides I&E on advanced health biotechnologies to
the public.
In Thailand, there are currently no effective programs
to help health professionals update their knowledge on
advanced health biotechnologies. Moreover, there is no
license revalidation policy for health professionals, des-
pite an attempt a few years ago to put one in place. In
the US, the NHGRI is planning to recommend to profes-
sional associations that they integrate genomic medicine
education into curricula and revalidation processes [40].
Approximately 30,000 doctors currently practice medi-
cine in Thailand, and every year 1,000 newly graduatedFigure 1 Milestones on the development of advanced health biotechphysicians enter the profession [41]. The majority of the
workforce graduated before the application of these bio-
technologies came into clinical practice. If more advanced
health biotechnologies are approved for the market, it
may be necessary to better regulate the provision of I&E
pertaining advanced health biotechnologies by sales re-
presentatives to Thai physicians and other health profes-
sionals because of its importance [42,43]. Alternatively, or
in addition, it may be useful for private companies who
are involved in these technologies to invest in professional
I&E rather than public. (Figure 1 provides a timeline of
key events in the area in Thailand).
Establishment of a specialised institute for advanced
health biotechnologies
Having identified a number of significant gaps in the
current system involving advanced health biotechnologies
in Thailand, and mindful of the lessons learnt from the
EU and US that are outlined above, we identified the need
to establish an organisation focusing on advanced health
biotechnologies in Thailand (sharing some characteristics
with the Andalusian Initiative for Advanced Therapies
[18,19] or the CIRM [28]). Such an organisation could be
entitled the ‘Advanced Health Biotechnologies Institute’
(‘AHBI’) and would be tasked with overseeing the tech-
nologies under the scope of our study as well as other
advanced health biotechnologies, such as nanomedicines.
It should be an autonomous institute established outside
the umbrella of the Ministry of Public Health and NSTDA
of the Ministry of Science and Technology, because of the
complex factors and implications involved with regulatingnologies in Thailand during 2002–2012.
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health, animal health, human health, and science charac-
teristics. This is to avoid political conflict between the two
Ministries, and is also aligned with the establishment of
the National Research Council, under the Office of the
Prime Minister rather than any particular Ministry.
The proposed responsibilities of this institute are as
follows:
 To provide national policy directions regarding R&D
and related infrastructure, clinical application, I&E,
and capacity strengthening, with reference to all
stakeholders.
 To provide research funding (including setting
priorities for research and developing human
resources).
 To provide ethical/scientific approval for research.
 To issue guidelines on good practice and clinical
practice.
 To provide public I&E and ensure that the quality of
information offered by other public organisations is
of the requisite standard.
 To create a certification system, similar to the
HONCode system, to control the quality of
information published in websites, leaflets, magazines,
and other media. This information should then be
collated into a public database, which can serve as a
resource for the public (including healthcare
professionals) to access validated data on advanced
health biotechnologies [44,45].
 To cooperate with the school consortia of health
professions for formal education, and the Royal
Colleges to plan for and develop strategies relating
to continuing education for health professionals
after formal education.
 To strengthen existing regulatory bodies
(Department of Health Service Support, TFDA,
Bureau of Sanatorium and Art of Healing, MC),
to provide support for approval and post-approval
activities, and cooperate with the Consumers’
Protection Office, TFDA and MC, in terms of
advertisements and complaints.
Particular recommendations for five key areas in Thailand
Research and development
It is essential that a national policy regarding R&D for
advanced health biotechnologies in Thailand be esta-
blished, including a prioritisation framework and scope.
This national policy would be introduced not only by
the ‘AHBI’ but also by other public fund-holders, such
as the NRC and the NSTDA. To better respond to the
rapid progress of the field, we recommend that the na-
tional strategic plans be five-yearly, with an option of
rolling revision if needed. The plan should be developedunder the ‘AHBI’ by a multi-sectoral team, including
health professionals, scientists, policy researchers, pa-
tient groups, and the private sector. The national plan
should include clear targets, and evaluation of its
impacts in terms of population health, innovation, and
national economics and competitiveness is also needed.
It is anticipated that the R&D market for advanced
health biotechnologies will gradually develop; it is also
likely that this market will be monopolised by one or a
few firms. This may differ from the market in advanced
economies because Thailand has a relatively small ser-
vice market and limited human resources for R&D. The
government should have strategies in place to avoid
monopolies by private manufacturers or providers. Start-
ing from the R&D process, the ‘AHBI’ should facilitate
PPPs in an appropriate manner; particular care should
be taken to avoid over-reliance on a single group of
scientists or one private firm.
As previously discussed, as there is unlikely to be suffi-
cient incentive for the private sector to invest in the
R&D of advanced health biotechnologies as opposed to
conventional health technologies, we recommend that
the government allocate more resources to this field, to
ensure that the public can take advantage of the benefits
it offers. In addition, funding should be provided in a
long-term, collaborative way, rather than on a year-by-
year basis, as evidence suggests that it takes at least eight
years to develop a final advanced health biotechnologies
product [29]. This justification has informed funding
policy in Europe and the US, as is evident from the ap-
proach of the CIRM and others. Furthermore, ethical
standards for R&D must be clearly set by the ‘AHBI’ in
order to avoid research misconduct. To this end, the
‘AHBI’ first needs to strengthen the capacity of the med-
ical ethics committees through training. Secondly, for
projects that are controversial or pose high risk of harm,
the ‘AHBI’ should be ultimately responsible for apprais-
ing them [46]. Lastly, the ‘AHBI’ should open channels
for complaints against suspected violation of research
ethical standards.
Authorisation
We anticipate regulatory gaps and stress the need for col-
laboration among regulatory bodies to address these
shortcomings, which include a lack of common defini-
tions/classifications used by all regulators. Therefore, we
recommend that the ‘AHBI’ work in conjunction with all
stakeholders to establish agreed definitions/classifications
of advanced health biotechnologies in Thailand. This can
be done after conducting a review of experiences in the
US, EU, and other Asian countries that are active in this
field.
Second, regarding the approval of products, we recom-
mend that the TFDA expand its current limited capacity
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health biotechnologies. Currently, there is a gap in that
there is no legal authority to approve individual health ser-
vices (e.g., stem cell treatment). Although Royal Colleges
in Thailand do play a role in setting standard clinical prac-
tice, this is informal. We recommend that the Bureau of
Sanatorium and Art of Healing, in collaboration with the
Royal Colleges, approves the use of individual advanced
health biotechnology services, because of the uncertainties
of safety and effectiveness, and the social and ethical
implications.
In addition, the criteria for the authorisation of products
and individual services should be harmonised using a
modified framework for priority setting, as described
above. Moreover, the developed framework should fully
engage all relevant stakeholders (e.g., insurance managers,
ethicists, HTA researchers, religious leaders, NGO repre-
sentatives, etc.). The ‘AHBI’ should also play a consultation
role for all regulatory bodies regarding the authorisation
of advanced health biotechnologies. Another shortfall that
needs to be addressed is the lack of capacity among regu-
lators. We propose that the ‘AHBI’ invest in the capacity
strengthening of regulators across the system, to ensure
that there is uniformity across national policy and that,
within networks, all knowledge and skills that are offered
are relevant and up to date.
Post-authorisation
We expect that post-authorisation activities will be critical
in the field of advanced health biotechnology because, as
discussed, there is, as yet, no established requirement on
evidence for authorisation; this means that many rando-
mised controlled trials, if available, are likely to be so small
that they cannot confirm long-term safety and effective-
ness. Therefore, we offer the following recommendations
for four elements of post-authorisation:
Post-marketing surveillance/withdrawal The imple-
mentation of a stronger surveillance system, one which
extends to patient registries, is necessary. So too is a risk
management and a long-term monitoring and reporting
system, which should be developed and maintained by
manufacturers, working closely with health providers.Table 1 Information and education targets according to level











Note: in the case of PGx tests, efficacy and effectiveness should be replaced with vaGuidelines provided by the ‘AHBI’ should be followed by
manufacturers (including hospitals), and those who do
not comply should be held liable.
Quality assurance of laboratories in the service sector
Reinforcement of good practice guidelines should fall
under the responsibility of the DMSc, and capacity
strengthening should be provided by the ‘AHBI’. Quality
assurance and the inspection of laboratories in the ser-
vice sector should be conducted by the DMSc in collab-
oration with the TFDA.
Quality assurance of medical services The ‘AHBI’ and
the Royal Colleges should set the medical standards for
those well-established advanced health biotechnologies
that already have proven safe and effective. This will not
only ensure quality of practice, but will also promote their
use. In light of the fact that national standards related to
conventional medical interventions were often established
once these interventions had been accepted for reim-
bursement (because payers want to estimate costs and
develop systems for monitoring and evaluation), we rec-
ommend that the standards for advanced health biotech-
nologies be set at the early stage of the introduction of
these advanced health biotechnologies.
Promotion/advertising regulation The ‘AHBI’ should
implement a system similar to the HONCode system to
certify the quality of information published in websites,
leaflets, magazines, and other media. This information
should then be collated into a public database, which
can serve as a resource for the public (including health-
care professionals) to access validated data on advanced
health biotechnologies. This is to complement the
TFDA’s activities.
Reimbursement
Because many advanced health biotechnologies are likely
to be expensive and will need close monitoring and
evaluation for cohort patients, we strongly suggest that
the reimbursement of these technologies be harmonised
across public health plans in Thailand to facilitate the
monitoring of safety and effectiveness. CED should beof evidence (partly based on [48])
ablished safety and efficacy,
effectiveness






lidity and utility, respectively.
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whose safety and effectiveness is as yet not fully proven.
This also facilitates access to interventions for patients in
need (complying with restricted criteria from both the
TFDA and insurance managers), while collecting more
evidence on effectiveness and safety.
Since Thailand has three major public health schemes
managed by different bodies (i.e., NHSO, the Comptroller
General’s Department, and the Social Security Office), we
recommend that the coverage decision-making body be
co-chaired by representatives of the three health schemes,
with technical support provided by the ‘AHBI’, relevant
professional associations, and HTA agencies. We recom-
mend that some relevant indicators from a European
framework be adopted (e.g., safety; knowledge/education;
broader health impacts; and social, ethical, legal, and or-
ganisational aspects) [47]. In addition, there should be
more collaboration between regulators, HTA agencies,
and insurance managers in relation to information ex-
change and post-marketing surveillance, including CED.
For those products that involve a service, such as a
medical/surgical procedure or diagnosis offered by the
private sector in public hospitals (and we believe that
most regenerative medicine technologies will take this
form), the development of new purchasing models be-
tween public health insurance plans and private compan-
ies is needed, to ensure both effective administration and
the equitable distribution of advanced health biotechno-
logy services across the country. In addition, revision of
the public procurement law is a necessary prerequisite be-
cause the current regulation does not allow private com-
panies to provide clinical services within public health
facilities.
Information and education
The ‘AHBI’ should be the organisation responsible for
the provision of I&E for all stakeholders. To maximise
the benefits that advanced health biotechnologies can
offer society, the ‘AHBI’ should classify I&E activities for
advanced health biotechnologies into three levels, and
target stakeholders accordingly (Table 1).
Conclusion
In this paper, we outline a set of recommendations that
aim to address the multiple gaps and weaknesses con-
cerning advanced health biotechnologies in Thailand,
ranging from underfunding of research to regulatory
deficits. We conclude that the establishment of a specia-
lised institute to fill the gaps in this area may represent
the most practical approach to tackle the existing defi-
ciencies in the Thai setting. Under a uniform national
strategic plan, the government should also invest more
in R&D and provide targeted I&E for all stakeholders in
this area. All regulators would also need to work to-gether with insurance providers and other stakeholders to
ensure the safety, effectiveness and quality of advanced
health biotechnologies. Moreover, the reimbursement of
advanced health biotechnologies should be harmonised
across public health plans in the country, and access to
new technologies should be provided to restricted pa-
tient groups, if any impact on population health is to be
realised.
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